Quality of life and new therapeutic options for metastatic castration-resistant prostate cancer

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Hilary Glen, MbChB, MSc, PhD, FRCP, of the Beatson West of Scotland Cancer Centre, Glasgow, UK, explains the clinical impact of emerging treatments, including abiraterone acetate and enzalutamide in both post-chemotherapy and pre-chemotherapy settings, on the care and quality of life of patients with metastatic castration-resistant prostate cancer.